Physician profile
Sandy Goldman
NPI 1902803760
$5,286.02
in general payments reported to CMS, 2019-2025
34 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $801 · 2020: $862 · 2021: $799 · 2022: $601 · 2023: $1,255 · 2024: $835 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,942 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,942.49 |
| Education | $279.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $806.72 | 2020-2021 | |
| Abbvie INC. | $579.97 | 2019-2025 | |
| Janssen Biotech, INC. | $549.88 | 2021-2024 | Tremfya |
| Sun Pharmaceutical Industries INC. | $361.12 | 2020-2024 | Winlevi, Absorica Ld, Odomzo |
| Incyte Corporation | $314.47 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $306.44 | 2019-2024 | Oracea, Epsolay, Aklief |
| Pfizer INC. | $272.94 | 2019-2024 | |
| Arcutis Biotherapeutics, INC. | $219.94 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $208.47 | 2019-2023 | Adbry |
| Epi Health, LLC | $176.18 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $152.53 | 2019-2024 | |
| Encore Dermatology INC. | $149.29 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $144.11 | 2020-2024 | Dupixent |
| Almirall LLC | $135.46 | 2019-2024 | Klisyri |
| Boston Scientific Corporation | $120.16 | 2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $110.83 | 2022-2024 | |
| Prugen, INC. Pharmaceuticals | $107.59 | 2019 | |
| Allergan, INC. | $84.33 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $79.34 | 2019-2020 | |
| Amgen INC. | $72.77 | 2023-2024 | Otezla |
| Mayne Pharma Commercial LLC | $47.10 | 2019-2023 | |
| Promius Pharma LLC | $38.14 | 2019 | |
| Biofrontera INC. | $37.31 | 2019-2020 | |
| Journey Medical Corporation | $32.47 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $23.91 | 2019 | |
| Medtronic Vascular, INC. | $23.01 | 2019 | |
| Lilly USA, LLC | $22.16 | 2023 | Olumiant, Taltz |
| Celgene Corporation | $18.79 | 2019 | |
| Dusa Pharmaceuticals, INC. | $18.00 | 2019 | |
| Aclaris Therapeutics, INC. | $17.69 | 2019 | |
| Sebela Pharmaceuticals INC. | $15.10 | 2021 | |
| Ucb, INC. | $14.96 | 2021 | |
| Dermavant Sciences, INC. | $14.00 | 2022 | |
| Strata Skin Sciences, INC. | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Goldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.